title: Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.
abstract: Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.
authors.affiliation: Department of Internal Medicine, Vanderbilt University Medical Center, D-3100 Medical Center North, Nashville, TN 37232-2358, USA. wade.t.iams@vanderbilt.edu
authors.forename: Wade
authors.initials: W
authors.lastname: Iams
authors.forename: Kathyrn Eby
authors.initials: KE
authors.lastname: Beckermann
authors.forename: Anne T
authors.initials: AT
authors.lastname: Neff
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
authors.forename: Vandana Gupta
authors.initials: VG
authors.lastname: Abramson
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D057049:Thrombotic Microangiopathies / Q000139:chemically induced*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab
references.citation: Medicine (Baltimore). 2012 Jul;91(4):195-205
references.pmid: 22732949
references.citation: Drug Saf. 2001;24(7):491-501
references.pmid: 11444722
references.citation: Cancer. 1989 Sep 1;64(5):1017-20
references.pmid: 2667747
references.citation: N Engl J Med. 2002 Aug 22;347(8):589-600
references.pmid: 12192020
references.citation: DICP. 1989 Jul-Aug;23(7-8):582-8
references.pmid: 2669373
references.citation: J Vasc Interv Radiol. 2009 Feb;20(2):275-6
references.pmid: 19054690
references.citation: Cancer. 1993 Mar 1;71(5):1882-92
references.pmid: 8448753
references.citation: Br Med J. 1952 Oct 25;2(4790):897-903
references.pmid: 12978378
references.citation: ISRN Hematol. 2012;2012:310596
references.pmid: 22888446
references.citation: J Clin Oncol. 1985 May;3(5):723-34
references.pmid: 3923162
references.citation: Med Oncol. 2010 Dec;27(4):1057-9
references.pmid: 19847680
references.citation: Ther Apher Dial. 2004 Apr;8(2):102-11
references.pmid: 15255125
references.citation: Bone Marrow Transplant. 1996 Jul;18(1):193-8
references.pmid: 8832014